CellaVision AB (publ) (CEVI) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

The participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Simon Ostergaard. Please go ahead. Thank you very much. And thanks to everyone taking the time to listen in to our quarterly report that we've launched this morning for our third quarter. I'm happy to say that I also have our interim CFO, Monica Jensen, with me and will be happy to also answer any questions you may have when we get to that part of the session. So the quarter in brief. And so we have named our quarter report soft quarter with mixed regional performance. And this is also related to currency effects. We saw Americas and EMEA. We had some quarterly variations resulting in modest growth, which we are highlighting here. We are coming out with a quarter here where we are reporting net sales decreased by 1.7 percentage points to 176 million. However, due to the FX headwind of minus 4.3%, then sales increased organically by 2.6% during this quarter versus the comparable quarter last year. On the EBITDA side, we increased our EBITDA to 50 million, so we increased by 1 million, and this relates to or corresponds to an EBITDA margin of 28%, also a small increase. In terms of what we want to highlight with regards to our strategic direction and our progress, we actually see a lot of progress. It's a very exciting time for the company and our partner. We're highlighting the fact that we've completed our clinical trial. We've submitted our documentation to receive the C mark for our bone marrow application. We do expect this one to be done according to plan and obtain the CMOD by, here we say, early 2026. I think we've set Q1, so that's still in lin...